The historical rank and industry rank for Beam Therapeutics's Net Margin % or its related term are showing as below:
MEX:BEAM'
s Net Margin % Range Over the Past 10 Years
Min: -810800 Med: -593.13 Max: -35.09
Current: -39.66
MEX:BEAM's Net Margin % is ranked better than 57.93% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs MEX:BEAM: -39.66
Beam Therapeutics (MEX:BEAM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Beam Therapeutics Net Margin % Related Terms
Beam Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs DNLI, ORKA, DYN: Net Margin % Comparison
For the Biotechnology subindustry, Beam Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (MEX:BEAM) has a Net Margin % of -297.18% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #398 out of 946 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Beam Therapeutics' Net Margin % too high?
Beam Therapeutics' current Net Margin % is -297.18%. Based on the distribution chart, Beam Therapeutics ranks #398 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Net Margin % compare to DNLI and ORKA?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #398 out of 946 companies for Net Margin %. This puts Beam Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Net Margin % is -297.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN541.64, compared to a current price of MXN628.46 — trading 16% above its estimated fair value. The current Net Margin % is -297.18%. Beam Therapeutics' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Net Margin % is -297.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 16% above its estimated GF Value™ of MXN541.64.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
Net Margin %: -297.18%
GF Value™: MXN541.64 vs. price of MXN628.46 (16% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score
Get the complete analysis for MEX:BEAM
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
